Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)

被引：0
|
作者：
Kuzuya, T. [1 ]
Yamashita, T. [2 ]
Takehara, T. [3 ]
Aikata, H. [4 ]
Kato, N. [5 ]
Hiasa, Y. [6 ]
Nakamura, S. [7 ]
Morimoto, N. [8 ]
Moriguchi, M. [9 ]
Ikeda, M. [10 ]
Inoue, J. [11 ]
Tani, J. [12 ]
Ueno, Y. [13 ]
Chayama, K. [14 ]
Tateishi, R. [15 ]
Kawamura, Y. [16 ]
Furuse, J. [17 ]
Kudo, M. [18 ]
Yamamoto, K. [19 ]
Kokudo, N. [20 ]
机构：
[1] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan
[2] Kanazawa Univ, Gastroenterol Dept, Kanazawa, Ishikawa, Japan
[3] Osaka Univ, Gastroenterol & Hepatol, Suita, Osaka, Japan
[4] Hiroshima Prefectural Hosp, Gastroenterol, Minami, Japan
[5] Chiba Univ, Sch Med, Gastroenterol, Chiba, Japan
[6] Ehime Univ, Grad Sch Med, Gastroenterol & Metabol, Toon, Japan
[7] Japanese Red Cross Soc, Himeji Hosp, Internal Med, Himeji, Hyogo, Japan
[8] Jichi Med Univ Hosp, Dept Med, Div Gastroenterol, Shimotsuke, Tochigi, Japan
[9] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan
[10] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan
[11] Tohoku Univ Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan
[12] Kagawa Univ, Fac Med, Grad Sch Med, Dept Gastroenterol & Neurol, Miki, Kagawa, Japan
[13] Yamagata Univ, Gastroenterol, Fac Med, Yamagata, Japan
[14] Hiroshima Univ Hosp, Collaborat Res Lab Med Innovat, Hiroshima, Japan
[15] Univ Tokyo Hosp, Dept Gastroenterol, Bunkyo ku, Tokyo, Japan
[16] Toranomon Gen Hosp, Hepatol, Minato, Japan
[17] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan
[18] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan
[19] Yokohama City Univ Med, Dept Biostat, Yokohama, Kanagawa, Japan
[20] NCGM Natl Ctr Global Hlth & Med, Surg, Shinjuku Ku, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
148P
引用
收藏
页码：S1531 / S1532
页数：2
相关论文
共 50 条
  • [41] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study
    Kim, Y. J.
    Kurosaki, M.
    Numata, K.
    Lim, H. Y.
    Ikeda, M.
    Kudo, M.
    Huang, Y-H.
    Shao, G.
    Kato, N.
    Kim, D-Y.
    Cho, S-B.
    Hsu, C-H.
    Lin, S-M.
    Jeng, L-B.
    Kuo, K-K.
    Mao, Y.
    Chewaskulyong, B.
    Khan, J.
    Ozgurdal, K.
    Qin, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1459 - S1460
  • [42] Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)
    Finn, Richard S.
    Ryoo, Baek-Yeol
    Hsu, Chih-Hung
    Li, Daneng
    Burgoyne, Adam
    Cotter, Christopher
    Badhrinarayanan, Shreya
    Wang, Yulei
    Yin, Anqi
    Edubilli, Tirupathi Rao
    Gane, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients- multicenter analysis
    Hiraoka, Atsushi
    Kumada, Takashi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kaibori, Masaki
    Tanaka, Takaaki
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Iijima, Hiroko
    Kosaka, Hisashi
    Hiasa, Yoichi
    Kudo, Masatoshi
    LIVER CANCER, 2023, 12 (03) : 209 - 217
  • [44] IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).
    Ducreux, Michel
    Zhu, Andrew X.
    Cheng, Ann-Lii
    Galle, Peter R.
    Ikeda, Masafumi
    Nicholas, Alan
    Verret, Wendy
    Li, Lindong
    Gaillard, Vincent E.
    Lencioni, Riccardo
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Safety/efficacy of atezolizumab plus bevacizumab during anti-platelet/anticoagulation therapy in unresectable hepatocellular carcinoma
    Moriguchi, Michihisa
    Okuda, Keiichiro
    Horiguchi, Go
    Kataoka, Seita
    Seko, Yuya
    Yamaguchi, Kanji
    Nishimura, Takeshi
    Fujii, Hideki
    Mitsumoto, Yasuhide
    Miyagawa, Masami
    Kirishima, Toshihiko
    Okishio, Shinya
    Hara, Tasuku
    Ishikawa, Hiroki
    Nagao, Yasuyuki
    Jo, Masayasu
    Ishii, Michiaki
    Tanaka, Saiyu
    Yamauchi, Norihito
    Mitsuyoshi, Hironori
    Nakajima, Tomoki
    Taketani, Hiroyoshi
    Yano, Kota
    Arai, Masahiro
    Umemura, Atsushi
    Itoh, Yoshito
    LIVER INTERNATIONAL, 2024, 44 (08) : 1751 - 1761
  • [46] The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients
    Aranda-Gutierrez, Alejandro
    Conde-Flores, Emilio
    Meraz-Brenez, Andres
    Escorza, Salvador
    Meneses-Medina, Monica I. Isabel
    Huitzil-Melendez, Fidel David
    de la Mora-Molina, Hector
    Rosas Camargo, Vanessa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Efficacy and safety of Atezolizumab plus Bevacizumab-based sequential treatment for unresectable hepatocellular carcinoma: a simulation model
    Celsa, Ciro
    Cabibbo, Giuseppe
    Battaglia, Salvatore
    Giuffrida, Paolo
    Rizzo, Giacomo Emanuele Maria
    Grova, Mauro
    Giacchetto, Marco
    Rancatore, Gabriele
    Stornello, Caterina
    Grassini, Maria Vittoria
    Badalamenti, Giuseppe
    Enea, Marco
    Craxi, Antonio
    Di Marco, Vito
    Camma, Calogero
    JOURNAL OF HEPATOLOGY, 2022, 77 : S387 - S388
  • [48] Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) plus bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
    Yopp, A.
    Kudo, M.
    Chen, M.
    Cheng, A-L.
    Kaseb, A. O.
    Lee, H. C.
    Qin, S.
    Cha, E.
    Hack, S. P.
    Lian, Q.
    Spahn, J.
    Wu, C.
    Chow, P.
    ANNALS OF ONCOLOGY, 2024, 35 : 1230 - 1230
  • [49] Atezolizumab plus bevacizumab (A plus B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network
    Cosgrove, David
    Tan, Amie
    Osterland, Andrew
    Hernandez, Sairy
    Ogale, Sarika
    Mahrus, Sami
    Murphy, John
    Wilson, Thomas W.
    Patton, Gregory A.
    Loaiza-Bonilla, Arturo
    Singal, Amit G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 447 - 447
  • [50] Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study
    Kim, Ji Hoon
    Nam, Hee-Chul
    Kim, Chang-Wook
    Cho, Hee Sun
    Yoo, Jae-Sung
    Han, Ji Won
    Jang, Jeong Won
    Choi, Jong Young
    Yoon, Seung Kew
    Yang, Hyun
    Bae, Si Hyun
    Kim, Suho
    Oh, Jung Suk
    Chun, Ho Jong
    Jeon, Chang Ho
    Ahn, Jaegyoon
    Sung, Pil Soo
    CANCERS, 2023, 15 (17)
12345